The bacterium Clostridioides difficile (C. difficile) forms organelles that help them defend against iron in the colon. According to a group of scientists from Vanderbilt University, this pathogen, which causes serious gastrointestinal infections, expresses fez genes to build structures called ferrosomes that store excess iron that is toxic to it. Its ferrosomes are surrounded by membrane and could be a target against this microorganism. Read More
The FDA has awarded orphan drug designation to Neoimmunetech Inc.'s NT-I7 (efineptakin alfa, rhIL-7-hyFc) for the treatment of acute radiation syndrome (ARS). NT-I7, a novel long-acting recombinant human IL-7, has the potential to rapidly recover and improve the immune response following a high dose of radiation exposure. Read More
Omega Therapeutics Inc. has presented preclinical data on hepatocyte nuclear factor 4-alpha (HNF4A) modulation in fibrotic liver disease models to enhance its key role and suggest it as a potent therapeutic target. Read More
Researchers from New York University College of Dentistry’s Pain Research Center in collaboration with the University of Pittsburgh found a candidate for chronic pain treatment among a library of 27 million compounds. Read More
Mira Pharmaceuticals Inc. has entered into a licensing agreement with Miralogx LLC for exclusive rights in the U.S., Canada and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analogue for depressive disorder treatments. Read More
Researchers from The Brigham and Women's Hospital presented data from a study that aimed to evaluate the role of somatic variants in drug-resistant mesial temporal lobe epilepsy (MTLE). High-coverage whole-exome sequencing was conducted using DNA samples derived from the hippocampus and paired brain tissue and/or blood samples. Read More
Astrazeneca AB has disclosed bicyclic heteroaromatic compounds acting as transcriptional enhancer factor (TEAD) and TEAD-4 inhibitors reported to be useful for the treatment of cancer. Read More
Voltron Therapeutics Inc., a portfolio company of Lucius Partners LLC, has finalized the protocol for a preclinical dose-ranging efficacy study of VTX-0P4, a protein-based cancer vaccine targeting prostate stem cell antigen (PSCA), a key target in the treatment of prostate cancer. Read More
Erasca Inc. has synthesized tricyclic pyridones and pyrimidones acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer. Read More
Hookipa Pharma Inc. has received clearance from the FDA for its IND application for HB-500, a novel arenaviral therapeutic vaccine for the treatment of HIV. Read More
Saniona AB has initiated the candidate selection phase with a proprietary subtype selective frontrunner molecule from its Kv7 lead optimization program for epilepsy. Read More
Daiichi Sankyo Co. Ltd. and Kyoto Pharmaceutical Industries Ltd. have identified Kelch-like ECH-associated protein 1 (Keap1)/Nrf2 interaction inhibitors reported to be useful for the treatment of acute lung injury, chronic kidney disease, autism, Alzheimer's disease, dry eye, heart failure, psoriasis and Sjögren's syndrome, among others. Read More
Researchers from Ipsen Ltd. and affiliated organizations presented the discovery and preclinical characterization of a novel NTCP inhibitor, A-7387, being developed for the treatment of HBV and HDV infections. Read More
Amyotrophic lateral sclerosis (ALS) is a disorder that leads to progressive muscle weakness and loss of muscle control due to affectation of the motor neurons. Increasing evidence points to defects in the nuclear envelope, which leads to disease progression. Read More
Arigenx Therapeutics Co. Ltd. has divulged substituted pyrimidine hydrazide compounds acting as aryl hydrocarbon receptor (AhR) antagonists reported to be useful for the treatment of cancer. Read More
Medicovestor Inc. has successfully completed an oversubscribed seed financing round with the aim of advancing its antibody-drug conjugate (ADC) platforms and drug candidates. Read More
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has described sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain. Read More
